10,000 UK genomes project explores the contribution of rare variants to human disease and its risk factors
Landmark study confirms complexity and informs the next stages of research
The largest population genome sequencing effort to date is published today in Nature. A series of papers describing resources and application of the data is published at the same time in Nature, Nature Genetics, Bioinformatics and Nature Communications.
Rare genetic variants are changes in DNA that are carried only by relatively few people in a population. The UK10K study was designed to explore the contribution of these rare genetic variants to human disease and its risk factors.
“The project has made important new contributions towards describing the role of rare genetic variants in a broad range of disease scenarios and human traits. It has shown that the value of sequencing a few thousand individuals is high for highly penetrant, rare diseases, but that for complex traits and diseases much larger sample sizes will be required in future studies. The data and results produced by this project will be instrumental for these future efforts.”
Dr Nicole Soranzo Corresponding author from the Wellcome Trust Sanger Institute
The project studied nearly 10,000 individuals, both healthy and affected by disease. The conditions included very rare disorders inherited in families, and more common diseases such as autism, schizophrenia and obesity. In healthy people, 64 different biomedical risk factors such as blood pressure or cholesterol levels were studied. By characterising the DNA sequence of these individuals, the project gained insight into the contribution of rare variants to a broad range of disease scenarios, and discovered new genetic variants and genes underpinning disease risk.
“The UK10K project has increased the resolution of genetic discoveries. It has enabled access to a much denser set of variants within the genome in the UK population, which can be used to refine our understanding of genetic effect on phenotypic traits. In earlier studies either very rare variants with big effects or common variants, which usually only have small effects, could be analysed. Now we have been able to explore an increased part of the spectrum of variation in between the very rare and the common ones.”
Dr Richard Durbin Senior UK10K researcher at the Sanger Institute
A series of papers published today in Nature and Nature Genetics in collaboration with other investigators demonstrates the value of these data for genetic discoveries.
As efforts continue to characterise the genetic underpinnings of complex diseases, the data and results of this study are expected to enable the next wave of discoveries. The UK10K sequence reference panel, described in greater detail in a companion paper published in Nature Communications, has been shown to greatly increase the ability to characterise rare variants in large population samples available to the worldwide research community. This resource will enable researchers to ‘fill in’ missing data from lower resolution genotype studies, allowing them to explore full genotypes more quickly and cheaply.
In addition, the authors have developed a web-based browser of association based on the Dalliance platform, described in a companion paper in Bioinformatics. This genome browser allows the easy retrieval of association results for all disease risk traits analysed in the study. Scientists investigating these specific disease risk factors will be able to directly access the consequence of a person’s DNA sequence to see how common any genetic variants they have are and what traits these variations are associated with.
“The UK10K project was an enormous undertaking and has laid the ground for future studies. For instance, the benefits of the new UK10K haplotype reference panel are already being realised in analyses of international consortia as well as the 0.5M people UK BioBank study.”
Klaudia Walter A leading author from the Sanger Institute
If you need help or have any queries, please contact us using the details below.
Notes to Editor
Also appearing in Nature Genetics:
Sidore C et al. Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. Nature Genetics 2015. DOI: 10.1038/ng.3368
Danjou F et al. Genome-wide association analyses based on whole-genome sequencing in Sardinia provide insights into regulation of hemoglobin levels. Nature Genetics 2015. DOI: 10.1038/ng.3307
Zoledziewska M et al. Major height reducing variants and selection for short stature on the island of Sardinia. Nature Genetics 2015 DOI: 10.1038/ng.3403
The Wellcome Trust provided funding for UK10K (WT091310). Additional grant support and acknowledgements can be found in the paper.
The UK10K project will enable researchers in the UK and beyond to better understand the link between low-frequency and rare genetic changes, and human disease caused by harmful changes to the proteins the body makes
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
7 Jul 2020
Drug screens and CRISPR combine to help make better cancer drugs
Improved understanding of the biological mechanisms underpinning drug response will enable faster, more efficient drug development
26 Jun 2020
The first draft human genome at 20
A revolution powering today’s advances in genomics, biology and medicine